...
首页> 外文期刊>Journal of Medical Case Reports >Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report
【24h】

Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report

机译:在干扰素治疗后艾滋病毒感染者艾滋病毒感染男性的系统性红斑狼疮的开发和管理:案例报告

获取原文
           

摘要

Introduction The association of human immunodeficiency virus and immune dysfunction leading to development of autoimmune markers is well described, but human immunodeficiency virus infection is relatively protective for the development of systemic lupus erythematosus. In contrast, development of systemic lupus erythematosus with hepatitis C and with interferon therapy is well described in a number of case reports. We here describe the first case of systemic lupus erythematosus developing in a man infected with human immunodeficiency virus, hepatitis C and hepatitis B co-infection where the onset seems to have been temporally related to interferon therapy. Case presentation We report the occurrence of systemic lupus erythematosus complicating interferon-α therapy for hepatitis C in a 47-year-old asplenic male with haemophilia co-infected with human immunodeficiency virus and hepatitis B. He presented with a truncal rash, abdominal pains and headache and later developed grade IV lupus nephritis requiring haemodialysis, mycophenolate mofetil and steroid therapy. We were able to successfully withdraw dialysis and mycophenolate while maintaining stable renal function. Conclusion Interferon-α is critical in antiviral immunity against hepatitis C but also acts as a pathogenic mediator for systemic lupus erythematosus, a condition associated with activation of plasmacytoid dendritic cells that are depleted in human immunodeficiency virus infection. The occurrence of auto-antibodies and lupus-like features in the coinfections with hepatitis C require careful assessment. Immunosuppressant therapy for lupus risks exacerbating underlying infections in patients with concurrent human immunodeficiency virus, hepatitis B and C.
机译:引言人类免疫缺陷病毒和免疫功能障碍导致自身免疫标记的发展的关联得到了很好的描述,但人类免疫缺陷病毒感染对系统性狼疮性红斑的发展相对保护。相比之下,在许多案例报告中,含有丙型肝炎和干扰素治疗的系统性狼疮红斑的发展得到了很好的描述。我们在这里描述了在感染人类免疫缺陷病毒,丙型肝炎和乙型肝炎的男人中发育的系统性红斑狼疮的第一种案例,丙型肝炎和乙型肝炎的共同感染似乎已经与干扰素治疗有关。案例介绍我们报告了Systemic Lupus红斑的发生,使47岁的抛弃男性与人类免疫缺陷病毒和乙型肝炎共同感染的47岁的抛养男性中丙型肝炎的干扰素-α治疗。他介绍了腹痛,腹痛头痛,后来发育了IV级狼疮肾炎,需要血液透析,霉酚酸酯,类动物疗法。我们能够在保持稳定的肾功能的同时成功提取透析和霉菌酸盐。结论干扰素-α对丙型肝炎的抗病毒免疫力是至关重要的,但也用作全身狼疮红斑狼疮的致病介质,其与激活血浆胸腺细胞的活化相关的病症,这些病症在人免疫缺陷病毒感染中耗尽。丙型肝炎辛纤维中的自动抗体和狼疮样特征的发生需要仔细评估。免疫抑制治疗狼疮风险加剧患者患者的潜在感染,乙型肝炎和C.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号